



Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV

Susan Zolla-Pazner^a, Raymond Alvarez^a, Xiang-Peng Kong^b,
and Svenja Weiss^a

Purpose of review

In humans, only one independent immunologic correlate of reduced risk of HIV infection has been identified: a robust antibody (Ab) response to the V1V2 domain of the gp120 envelope (Env) protein. In recent years, the presence and level of V1V2-specific Abs has also been correlated with protection from SIV and SHIV infections. Here, we review the multitude of studies showing the in-vivo protective effects of V1V2 Abs and review their immunologic characteristics and antiviral functions.

Recent findings

Structural and immunologic studies have defined four epitope families in the V1V2 domain: one epitope family, V2q, which preferentially presents as a quaternary structure of the Env trimer, and another epitope family (V2qt) which requires the quaternary trimeric Env structure; these two epitope types are recognized by two families of monoclonal Abs (mAbs)—V2q-specific and V2qt-specific mAbs—which display broad and potent neutralizing activity. A third epitope family, V2i, is present as a discontinuous conformational structure that overlays the $\alpha 4\beta 7$ integrin binding motif, and a fourth epitope family (V2p) exists on V2 peptides. Antibodies specific for V2i and V2p epitopes display only poor neutralizing activity but effectively mediate other antiviral activities and have been correlated with control of and/or protection from HIV, SIV and SHIV. Notably, V2q and V2qt Abs have not been induced by any vaccines, but V2p and V2i Abs have been readily induced with various vaccines in nonhuman primates and humans.

Summary

The correlation of vaccine-induced V2p and V2i Abs with protection from HIV, SIV and SHIV suggests that these Ab types are extremely important to induce with prophylactic vaccines.

Keywords

antibodies, antiviral functions, epitope, nonhuman primates, V2, vaccines

INTRODUCTION

The key to the rational design of an effective HIV vaccine depends on the identification of immune correlates of protection and immunologic mechanisms that prevent HIV acquisition. The first independent correlate of reduced risk of HIV infection in humans was identified by studies of participants in the RV144 clinical vaccine trial: a robust antibody (Ab) response to the V1V2 region of the virus gp120 envelope (Env) glycoprotein. Similar correlations were subsequently identified in studies of nonhuman primates (NHPs) between protection from SIV and SHIV and V2 Ab levels. Here, we summarize these human and NHP findings and the V2 Abs that are involved in the control of and/or protection from HIV, SIV and SHIV.

^aDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai and ^bDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, USA

Correspondence to Susan Zolla-Pazner, PhD, Professor of Medicine, Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1090, New York, NY 10029, USA. Tel: +1 212 241 2781; e-mail: Susan.Zolla-Pazner@mssm.edu

Curr Opin HIV AIDS 2019, 14:309–317

DOI:10.1097/COH.0000000000000551

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

KEY POINTS

- V2-specific nonneutralizing Abs are involved in the control of and/or protection from HIV, SIV and SHIV.
- The V2 Abs that correlate with protection after active or passive immunization are specific for the continuous epitope in the C-strand of V2 and/or for a discontinuous epitope that includes residues in V1 and V2, including the tripeptide $\alpha 4\beta 7$ integrin binding motif in V2 (V2p and V2i Abs, respectively).
- Fc-mediated antiviral Ab activities play an important role in control of and/or protection from HIV, SIV and SHIV infection.

STRUCTURAL AND IMMUNOLOGIC CHARACTERIZATION OF THE V1V2 DOMAIN

Studies of polyclonal sera from HIV-infected individuals have established that, over time, infection generates different ‘humoral fingerprints’ [1]. This is true for patterns of Ab specificities, subclasses and antiviral activities [2–5,6^{*}]. Similar findings pertain to Abs induced by vaccines targeting SIV [7^{*},8] and SHIV [9–12]. Given the association between V2 Abs and protection in human and animal models, it is critical to understand the complexity of the V1V2 domain of the virus Env and the Ab response to it.

Conformational complexity of V1V2

In HIV, the V1V2 domain, like the rest of gp120, exhibits marked conformational flexibility. The V1V2 domain serves as the ‘trimer association domain’ at the apex of the closed trimeric Env, but the V1V2 domain of each of the three gp120 protomers opens out when gp120 interacts with

CD4 [13–15,16^{*}]. The C-strand of V2, composed of amino acids (AAs) 170–176, one of the five strands composing the V1V2 β -barrel, exists in different conformations, varying between a β -strand and an α -helix [17–19], where the β -strand configuration is preferentially present in the closed, structurally constrained trimeric Env, whereas the α -helical conformation is preferred where there is less structural constraint when the Env is fully open. The preferred configuration is undoubtedly affected by the sequence of V1 and V2, substitutions at key residues, the molecular context in which the V1V2 domain is placed and the intraprotomer and interprotomer interactions of V1V2 within the Env trimer [20].

Alternative V2 conformational epitopes

As a result of this configurational complexity, there are at least four types of epitopes in the V1V2 region as shown in Fig. 1: V2q epitopes which preferentially recognize structures formed by the quaternary interaction of the three gp120 protomers and are glycan-dependent; V2q is recognized by V2q mAbs such as PG9 and PG16 [17,21–24]; V2qt epitopes which recognize quaternary, trimer-dependent V2 epitopes at the apical center of Env are recognized by several V2qt mAbs exemplified by PGT145 [25]; V2i epitopes which overlay the $\alpha 4\beta 7$ integrin binding site in V2 and are recognized by V2i mAbs such as 830A and 2158 [26–28]; and V2p epitopes which are presented by V2 linear and cyclic peptides, and recognized by V2p mAbs such as CH58 and CAP228-16H [19,29^{*},30^{*}]. The V2q, V2qt and V2i mAbs preferentially recognize their various epitopes when the C-strand of V2 is in the β -strand conformation. In contrast, V2p mAbs recognize the C-strand in its α -




FIGURE 1. Diagram of the position of the four epitope classes in the V1V2 region (V2p, V2i, V2q and V2qt), and examples of mAbs that target each of these epitopes.




FIGURE 2. Luminex reactivity of V2p mAb 8490 (a) and V2i mAb 697-30D (b) vs. cyclic V2 peptide (column 1), V1V2-tags (columns 2–4), V1V2-gp70 fusion proteins (columns 5–8), C5 peptide (column 9) and BSA (column 10).

helical configuration [19]. These four families of mAbs that recognize the various V1V2 epitopes display distinct patterns of reactivity; an example is shown in Fig. 2 in which the patterns of reactivity of V2p and V2i mAbs are shown vs. a panel of eight V2-bearing antigens.

The correlates of reduced risk in RV144

RV144 is the only clinical vaccine trial to date which provided a marginal but statistically significant reduced rate of infection [31] as well as an independent correlate of risk (COR) of HIV infection: an inverse relationship between the incidence of infection and the level of Abs binding to a V1V2_{CaseA2}-gp70 fusion protein [32–34]. The V1V2_{CaseA2}-gp70 fusion protein preferentially reacts with V2i mAbs, and indeed, several V2i mAbs have been selected from the cells of HIV-infected individuals using this reagent, and these V2i mAbs are highly cross-clade reactive [35,36]. In this context, it is noteworthy that while V1V2_{CaseA2}-gp70 carries the V1V2 sequence from a clade B strain [37], infections occurring in the RV144 participants were primarily because of clade AE (CRF01_AE), the predominant circulating strain in Thailand, and this

supports the hypothesis that the V2 Abs implicated in the inverse COR were cross-clade reactive.

Notably, in human vaccine studies other than RV144, the induction of highly reactive and functional V2-specific Abs has not been strong, for example in studies such as VAX003, VAX004 and HVTN100 [5,38,39]. It is hypothesized that the gp120 of the clade AE A244 strain used in RV144 is unusual in its ability to efficiently induce V2 Abs. Thus, for example, the immunogens used in HVTN100 [ALVAC-HIV (vCP2438) and bivalent Subtype C gp120s (1086 and TV1)], which was the precursor of the ongoing phase III HVTN702 study in South Africa, induced a markedly poorer V2 response than that attained in RV144 [38]. These findings are of particular interest in the context of recent studies in which robust V2i and V2p Ab responses have been elicited using V2-targeting vaccine constructs in rabbits [40,41] and NHPs [42]. Notably, in the latter study, the use of a trimeric V1V2_{A244}-scaffold fusion protein as part of an immunogen cocktail appeared to be particularly effective in inducing broadly reactive and functional V2 Abs.

In addition to the inverse COR with V2i Abs, a similar role for V2p Abs has been documented. Thus,

studies with plasma from RV144 vaccinees demonstrated an inverse COR in terms of the Ab response to linear V2 peptides tested by microarray [43], and the correlations of Abs cross-reactive with V2 peptides representing different HIV clades were at least as significant as the correlation seen with the primary variable generated using the V1V2_{CaseA2-gp70} fusion protein. As noted, linear and cyclic V2 (cV2) peptides preferentially assume a structure when complexed with specific V2p mAbs in which the C-strand is in an α -helical configuration [19,29[■],30[■]], and two such V2p mAbs were isolated from circulating cells of an individual receiving the RV144 vaccine regimen [19]. Thus, we know from polyclonal and mAb studies emanating from RV144 that V2p Abs recognizing the α -helix in the C-strand of V2 were induced by the RV144 vaccine and that they constitute an inverse COR ([43] and Table 1) [32,43–48,49[■],50,51,52[■]]. Additional V2p mAbs have recently been isolated from individuals infected with clade C [29[■],30[■]]. All of these V2p mAbs have been crystallized and reveal the targeted epitope in the V2 C-strand as an α -helix or helix-loop, and, like the plasma V2p polyclonal Abs in RV144 vaccinees [33], these mAbs are cross-clade reactive (Fig. 2A) [37].

THE ROLE OF V2 ABS IN THE CONTROL OF AND PROTECTION FROM SIV AND SHIV INFECTIONS IN NONHUMAN PRIMATES

The original observation of an inverse COR in RV144 has been supported by many subsidiary studies of the RV144 data [3,4,43,53,54]. Nonetheless, there are critics who remain skeptical of the RV144 correlates analyses [55]. This skepticism is now tempered by both active and passive immunization

studies from many laboratories showing correlates of protection from SIV and SHIV infection with the presence of V2 Abs (Table 1).

V2p-specific Abs protect against SIV infection

In an NHP vaccine study using vaccine regimens consisting of Ad26 and/or modified vaccinia Ankara vector-based vaccines expressing SIV_{SME543} gag, pol and Env antigens with subsequent intrarectal (i.r.) challenges with SIV_{mac251}, there was at least 80% reduction in per-exposure probability of infection [44]. The strength of Ab binding to a biotinylated cyclic V2 peptide from SIV_{SME543} correlated positively with the number of challenges required to establish infection ($P < 0.0001$).

Another NHP study utilized priming with gp160 DNA from SIV_{mac239} and boosting with recombinant Ad5_{SIVmac239} with subsequent multiple mucosal challenges with SIV_{E660} [47]. Among the significant humoral response correlates identified was the strength of binding of plasma IgG Abs to a V1V2_{SIVmac239} linear peptide with time to infection ($P = 0.009$). In this study, a sieving effect was also noted at a glycosylation site in V1V2 that conferred neutralization resistance. This is similar to the sieving signature identified in the RV144 human trial [53].

Additional studies in NHPs also support the role of V2-specific Abs in protection from or control of SIV. With sera from animals immunized with a regimen similar to that used in RV144, Ab assays revealed that the reduced risk of SIV_{mac251} acquisition correlated with the presence of mucosal IgG to cyclic V2 ($P = 0.0018$) [48,45]. In yet another study, where animals were immunized with gp120 protein and human papilloma pseudoviruses expressing

Table 1. Studies showing statistically significant correlations of V2-specific antibodies that correlate with protection from and/or control of HIV, SIV and SHIV

Year	Protection and/or control of	Correlation with Abs specific for	Immunization	Reference
2012	HIV	V2i	Active	Haynes <i>et al.</i> [32]
	SIV _{mac251}	V2p	Active	Barouch <i>et al.</i> [44]
2013	HIV	V2p	Active	Gottardo <i>et al.</i> [43]
	SIV _{mac251}	V2p	Active	Pegu <i>et al.</i> [45]
2014	SIV _{mac251}	V2p	Active	Gordon <i>et al.</i> [46]
2015	SIV _{E660}	V2p	Active	Roederer <i>et al.</i> [47]
2016	SIV _{mac251}	V2p	Active	Vaccari <i>et al.</i> [48]
2018	SHIV _{BaL}	V2i	Passive	Hessell <i>et al.</i> [49 [■]]
	SIV _{smE66}	V2p	Active	Singh <i>et al.</i> [50]
	SHIV _{BaL}	V2	Active	Hessell <i>et al.</i> [51]
	SHIV _{BaL}	V2p	Active	Weiss <i>et al.</i> [52 [■]]

SIV_{mac251} genes +/- ALVAC-SIV_{mac251}, a significant correlation was found between the number of challenges to achieve persistent infection with SIV_{mac251} and the avidity index for V1V2 Abs in blood ($P=0.014$) [46]. And most recently, in NHPs immunized with SIV_{mac251}-derived *env* plasmids and monomeric M766 gp120 protein followed by challenge with SIV_{E660}, inverse correlations were identified for plasma and mucosal V1V2 responses with peak viral load ($P=0.05$ and $P=0.01$, respectively), responses to cyclic V2 peptides with postpeak and chronic viremia ($P=0.01$ for each) and V2-specific responses with delayed virus acquisition and post-infection control [50]. Each of these experiments suggests that Abs that hampered SIV infection were of the V2p type which recognize the α -helical V2 C-strand configuration.

V2p Abs protect against SHIV infection

Most recently, an RV144-like vaccine regimen was tested in NHPs that were challenged with SHIV_{BaL} [51]. All three unimmunized animals were infected after two i.r. challenges, but in five of the nine immunized macaques, tight control of viremia was noted as reflected by only transient and low plasma viral load (PVL) measurements, with no measurable virus in tissues at necropsy 13 weeks after challenge. Luminex studies of the plasma from these animals showed a correlate of protection from SHIV_{BaL} with Abs of the V2p type that were reactive with V1V2₁₀₈₆-tags [19], a reagent in which the V2 C-strand preferentially adopts an α -helical conformation as shown by circular dichroism [52^o].

THE ROLE OF V2I ABS IN SHIV VIRAL CONTROL

To date, only indirect, correlative data have linked V2 Abs with protection in human and NHP experiments. The first direct in-vivo test of the hypothesis emanating from RV144 — that V2 Abs could reduce the risk of infection — was reported recently in experiments investigating the role of a passively administered V2i mAb in protection from, and/or control of infection in NHPs challenged i.r. with SHIV_{BaL} [49^o]. NHPs received 3 weekly doses at 10 mg/kg of the IgG1 isoform of the V2i mAb 830A ($n=12$), whereas control animals ($n=12$) received a dengue-specific mAb (DEN3) at the same times and doses. Animals were challenged with SHIV_{BaL} twice during each week that they received the passively transferred mAb. Blood specimens were drawn at regular intervals at the time of and after challenge, and animals were sacrificed and necropsied 6 weeks after infection. On the basis of SIV_{gag} RNA copies/ml in plasma, 11/12 control animals were infected by the sixth and final SHIV_{BaL} challenge dose, and while the 12th animal had no

detectable PVL, SHIV was detected in its liver at necropsy. Of the 12 animals receiving V2i mAb 830A, three had no detectable PVL at necropsy and no SIV_{gag} DNA was detected in their tissues. Of these latter three macaques, one was plasma aviremic after all challenge doses and two had only low and transient positive PVLs at a single time point. Compared in a grouped analysis, the PVL in the 830A recipients was significantly lower than that in the DEN3 controls ($P=0.031$). The cell-associated viral load (CAVL) DNA in peripheral blood mononuclear cells was assessed as virus copies collected during the course of the experiment, and a statistical analysis revealed a significant difference in CAVLs between controls and the IgG1 830A group ($P=0.038$). In addition, copy numbers of viral DNA in 13 different tissues were measured at the time of necropsy and revealed significant differences in the viral DNA loads between viremic 830A-treated and control macaques ($P=0.015$). Copy numbers of SIV_{gag} DNA associated with each tissue sampled from the 830A-treated macaques were compared individually to the corresponding tissue from animals in the control group and again significant differences in copy numbers were found in iliosacral, axillary and inguinal lymph nodes and from mixed tissues from the reproductive tract. Thus, while too few animals remained uninfected in the treated group to achieve statistical significance in terms of the risk of infection, the data demonstrate that the presence of the passively administered V2i 830A mAb had significant effects against SHIV challenge in macaques by reducing the viral infectious titer so that animals were either not infected or experienced lower level virus production in blood and tissues, reduced plasma virus load, and decreased viral DNA in lymphoid tissues. This is the first direct demonstration showing the ability of V2i Abs to impede SHIV infection [49^o].

The biologic functions of V2 antibodies

Neutralizing Abs were not an inverse COR in the RV144 vaccine trial, suggesting that non-neutralizing Ab effects were critical. These effects could be mediated by either the Fab portion of the Ab which binds to antigens on the surface of the virus or virus-infected cell and/or by the Fc portion of the Ab which binds to Fc receptors (FcRs) after the Fab fragment binds to its antigen.

Antiviral activities mediated by the Fab fragment of antibodies

Neutralization of virus infectivity is the most frequently measured antiviral activity, resulting as a function of the attachment of Abs to virions. However, several other phenomena belong to this

category of antiviral functions and appear to play a critical role *in vivo* [56]. These include:

- (1) Virus aggregation: Abs can bind to virions; when they do, they can aggregate viruses, enhancing their destruction via phagocytosis. It has been shown that there is a clear association between virus aggregation and virus phagocytosis [57], and this may play a role in reducing the virus inoculum upon exposure to the virus, resulting in a reduced risk of infection. Similarly, this mechanism may assist in the clearance of circulating virus, which, perhaps as a result, has a half-life in circulation of only approximately 0.3 days [58]. Monoclonal IgG and dimeric IgA Abs, as well as polyclonal purified serum IgA from RV144 participants, have been shown to aggregate HIV virions, and the specificities of the Abs used to do so include mAbs to various epitopes of both gp120 and gp41 [59].
- (2) Virus capture: This *in-vitro* assay has been used to demonstrate that the RV144 vaccine-elicited gp120-specific Abs of multiple specificities (V3, V2 and C1) can bind to virions [60]. These studies were extended to show that C1-specific and V2-specific mAbs derived from vaccinees acted in synergy to capture virions [54].
- (3) Inhibition of virus binding to cell-surface $\alpha 4\beta 7$: It was shown in 2008 that a tripeptide in the V2 loop of gp120 (at AA 179–181) constitutes a motif that mimics structures presented by the natural ligands of the $\alpha 4\beta 7$ integrin, a gut-

homing receptor, and that the HIV-1 envelope protein gp120 bound to an activated form of $\alpha 4\beta 7$ [61]. In a recent follow-up to the initial findings, the V2 domain of gp120 was shown to preferentially engage extended forms of $\alpha 4\beta 7$ in a cation-sensitive manner. A 15-mer V2-derived peptide (AA 168–181) can bind to $\alpha 4\beta 7$, and V2p-specific mAbs derived from vaccinated and infected individuals recognize this peptide and block the V2/ $\alpha 4\beta 7$ interaction [62]. Other laboratories have reproduced and extended these findings [63] and have shown that purified IgG from some uninfected RV144 vaccinees can also inhibit the V2/ $\alpha 4\beta 7$ interaction. These data suggest that anti-V2 Abs may play a role *in vivo*, blocking the gp120/ $\alpha 4\beta 7$ interaction and thus preventing HIV acquisition and/or controlling early targeting of the gut lymphoid tissues by the virus.

Fc-dependent effector functions

Many Abs Mediate antiviral effects because of their ability to bind to infected cells and/or virions, leading to conformational changes in the Fc fragment which allow it to bind to FcRs on the surface of various cell types such as T cells, monocyte/macrophages, polymorphonuclear granulocytes, dendritic cells, and so on. These Abs include both bnAbs and Abs that are poor or non-neutralizers, can be specific for various regions of the gp120 and gp41 Env proteins (Fig. 3 and [19,30,40,54,64–70]), and can bind to the Env trimer in its different states (closed, partially open or




FIGURE 3. Level of binding of mAbs to native-like Env. Results shown are for binding of mAbs to tetherin^{hi} Jurkat cells nucleofected with an mCherry+ NL4-3 reporter construct as described by Alvarez *et al.* [70]. Monoclonal Abs used (and the epitope for which they are specific) include: human antiparvovirus mAb (1418), A32 (anti-C1), b12 (CD4bs), 240 and 246 (gp41, cluster I), 447-52D (V3 crown), 697-30D (V2i), 830A (V2i), 2158 (V2i) and 10-1074 (V3-glycan).

fully open [16[¶]]). The Fc/FcR interaction initiates antiviral activities that include Ab-dependent cellular phagocytosis (ADCP) and Ab-dependent cellular cytotoxicity [2,4,54,71–73] as well as complement-mediated virolysis [39,74–76]. Many of these mechanisms have been associated with reduced risk of infection. For example, ADCP has been associated with reduced HIV infection risk in humans [39,77] and with SIV infection in NHPs [12], and Ab-dependent complement activation and deposition [78,79[¶]] as well as Ab-dependent cell-mediated viral inhibition have been shown to contribute to control of SIV and SHIV [80–83].

CONCLUSION

The first and only independent correlate of reduced risk of HIV infection in humans was identified by studies of participants in the RV144 clinical vaccine trial: a robust Ab response to the V1V2 region of the virus gp120 Env glycoprotein. Subsequent to this observation, several active and passive immunization studies in NHPs identified the presence and level of V2 Abs as correlates of protection from SIV and SHIV infections. Currently, 11 vaccine studies in humans and NHPs (summarized in Table 1) support the role of V1V2-specific Abs in protection. In each case, the Abs invoked displayed little or no neutralizing activity but mediated other antiviral activities. Protection was documented against viruses heterologous to the strains used in the vaccines. These studies suggest a new paradigm for vaccine development: protection from and/or control of infection can be achieved with Abs that are induced by existing vaccine constructs, are effective against heterologous viruses, do not display broad and potent neutralizing activity and mediate a variety of non-neutralizing Fab-mediated and Fc-mediated antiviral activities.

Acknowledgements

The authors thank Drs. David Easterhof and Barton Haynes for providing V2p mAb 8490.

Financial support and sponsorship

Funding received for this work came from the U.S. National Institutes of Allergy and Infectious Diseases (NIH grant P01 AI100151) and funds from the Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Liu P, Overman RG, Yates NL, *et al.* Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. *J Virol* 2011; 85:11196–11207.
 2. Chung AW, Kumar MP, Arnold KB, *et al.* Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. *Cell* 2015; 163:988–998.
 3. Yates NL, Liao HX, Fong Y, *et al.* Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. *Sci Transl Med* 2014; 6:228ra39.
 4. Chung AW, Ghebremichael M, Robinson H, *et al.* Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. *Sci Transl Med* 2014; 6:228ra38.
 5. Balasubramanian P, Williams C, Shapiro MB, *et al.* Functional antibody response against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 vaccine trials. *Sci Rep* 2018; 8:542.
 6. Yates NL, deCamp AC, Korber BT, *et al.* HIV-1 envelope glycoproteins from diverse clades differentiate antibody responses and durability among vaccinees. *J Virol* 2018; 92:; e01843-17.
- Analysis of vaccine-elicited V1V2 binding antibody in longitudinal samples from the RV144 clinical trial revealed a striking heterogeneity among individual vaccinees in maintaining durable responses. These data support the idea that a major goal for vaccine development is to improve antibody levels, breadth and durability at the population level.
7. Ackerman ME, Das J, Pittala S, *et al.* Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. *Nat Med* 2018; 24:1590–1598.
- The route of immunization plays a critical role for phagocytic Fc-effector Ab activity in protection from SIV, driving Fc activity via distinct innate effector cells and antibody isotypes. The same correlates predict protection from SHIV infection. Thus, functional humoral mechanisms initiated by distinct vaccination routes and immunization strategies are pivotal for inducing multiple, potentially complementary correlates of immunity.
8. Miller-Novak LK, Das J, Musich TA, *et al.* Analysis of complement-mediated lysis of simian immunodeficiency virus (SIV) and SIV-infected cells reveals sex differences in vaccine-induced immune responses in rhesus macaques. *J Virol* 2018; 92:.
 9. Bradley T, Pollara J, Santra S, *et al.* Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. *Nat Commun* 2017; 8:15711.
 10. Srivastava IK, Stamatatos L, Kan E, *et al.* Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. *J Virol* 2003; 77:11244–11259.
 11. Barnett SW, Srivastava IK, Kan E, *et al.* Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. *AIDS* 2008; 22:339–348.
 12. Barouch DH, Stephenson KE, Borducchi EN, *et al.* Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. *Cell* 2013; 155:531–539.
 13. Kwon YD, Finzi A, Wu X, *et al.* Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. *Proc Natl Acad Sci U S A* 2012; 109:5663–5668.
 14. Mao Y, Wang L, Gu C, *et al.* Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. *Nat Struct Mol Biol* 2012; 19:893–899.
 15. Munro JB, Gorman J, Ma X, *et al.* Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. *Science* 2014; 346:759–763.
 16. Wang H, Barnes CO, Yang Z, *et al.* Partially open HIV-1 envelope structures exhibit conformational changes relevant for coreceptor binding and fusion. *Cell Host Microbe* 2018; 24:579–592.e4.
- Cryo-electron micrographic structures of SOSIP with various Abs and/or CD4 reveal the structure of the displaced V1V2 and reveal its structures.
17. McLellan JS, Pancera M, Carrico C, *et al.* Structure of HIV-1 gp120 V1V2 domain with broadly neutralizing antibody PG9. *Nature* 2011; 480:336–343.
 18. Pan R, Gorny MK, Zolla-Pazner S, Kong XP. The V1V2 region of HIV-1 gp120 forms a five-stranded beta barrel. *J Virol* 2015; 89:8003–8010.
 19. Liao H-X, Bonsignori M, Alam SM, *et al.* Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. *Immunity* 2013; 38:1–11.
 20. Powell RLR, Totrov M, Itri V, *et al.* Plasticity and epitope exposure of the HIV-1 envelope trimer. *J Virol* 2017; 91; e00410-17.
 21. Gorny MK, Stamatatos L, Volsky B, *et al.* Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. *J Virol* 2005; 79:5232–5237.

22. Kimura T, Wang XH, Williams C, *et al.* Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins. *Hum Antibodies* 2009; 18(1–2):35–40.
 23. Pancera M, Zhou T, Druz A, *et al.* Structure and immune recognition of trimeric prefusion HIV-1. *Nature* 2014; 514:455–461.
 24. Walker LM, Phogat SK, Chan-Hui PY, *et al.* Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. *Science* 2009; 326:285–289.
 25. Lee JH, Andrabi R, Su CY, *et al.* A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. *Immunity* 2017; 46:690–702.
 26. Mayr LM, Cohen S, Spurrier B, *et al.* Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. *PLoS One* 2013; 8:e70859.
 27. Gorny MK, Moore JP, Conley AJ, *et al.* Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of HIV-1. *J Virol* 1994; 68:8312–8320.
 28. Nyambi PN, Mbah HA, Burda S, *et al.* Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. *J Virol* 2000; 74:7096–7107.
 29. Wibmer CK, Richardson SI, Ylitz J, *et al.* Common helical V1V2 conformations of HIV-1 Envelope expose the alpha4beta7 binding site on intact virions. *Nat Commun* 2018; 9:4489.
- Structural studies of the epitope recognized by new V2p mAbs derived from patients infected with HIV.
30. van Eeden C, Wibmer CK, Scheepers C, *et al.* V2-directed vaccine-like antibodies from HIV-1 infection identify an additional K169-binding light chain motif with broad ADCC activity. *Cell Rep* 2018; 25:3123–3135.e6.
- Functional studies of new V2p mAbs derived from HIV-infected individuals.
31. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, *et al.* Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med* 2009; 361:2209–2220.
 32. Haynes BF, Gilbert PB, McElrath MJ, *et al.* Immune correlates analysis of the ALVAC-AIDSVAX HIV-1 vaccine efficacy trial. *N Engl J Med* 2012; 366:1275–1286.
 33. Zolla-Pazner S, deCamp AC, Cardozo T, *et al.* Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. *PLoS One* 2013; 8:e53629.
 34. Zolla-Pazner S, DeCamp AC, Gilbert PB, *et al.* Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. *PLoS One* 2014; 9:e87572.
 35. Gorny MK, Pan R, Williams C, *et al.* Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from human immunodeficiency virus type 1-infected individuals. *Virology* 2012; 427:198–207.
 36. Pinter A, Honnen WJ, He Y, *et al.* The V1/V2 domain of gp120 is a global regulator of sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. *J Virol* 2004; 78:5205–5215.
 37. Pinter A, Honnen WJ, Kayman SC, *et al.* Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. *Vaccine* 1998; 16:1803–1811.
 38. Shen X, Moodie Z, McMillan A, *et al.* V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa. *HIV Research for Prevention*. Madrid. 2018. Abstract OA02.03.
 39. Perez LG, Martinez DR, deCamp AC, *et al.* V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. *PLoS One* 2017; 12:e0180720.
 40. Zolla-Pazner S, Powell R, Yahyaei S, *et al.* Rationally-designed vaccines targeting the V2 region of HIV-1 gp120 induce a focused, cross clade-reactive biologically functional antibody response. *J Virol* 2016; 90:10993–11006.
 41. Jiang X, Totrov M, Li W, *et al.* Rationally designed immunogens targeting HIV-1 gp120 V1V2 induce distinct conformation-specific antibody responses in rabbits. *J Virol* 2016; 90:11007–11019.
 42. Hessel AJ, Powell R, Jaing X, *et al.* Multimeric epitope-scaffold HIV vaccines target V1V2 and differentially tune polyfunctional antibody responses. *Cell Rep* 2019; in press.
 43. Gottardo R, Bailer RT, Korber BT, *et al.* Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 as correlates of infection risk in the RV144 vaccine efficacy trial. *PLoS One* 2013; 8:e75665.
 44. Barouch DH, Liu J, Li H, *et al.* Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. *Nature* 2012; 482:89–93.
 45. Pegu P, Vaccari M, Gordon S, *et al.* Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus (SIVmac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. *J Virol* 2013; 87:1708–1719.
 46. Gordon SN, Doster MN, Kines RC, *et al.* Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia. *J Immunol* 2014; 193:6172–6183.
 47. Roederer M, Keele BF, Schmidt SD, *et al.* Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. *Nature* 2014; 505:502–508.
 48. Vaccari M, Gordon SN, Fourati S, *et al.* Adjuvant-dependent innate and adaptive immune signatures of risk of SIV acquisition. *Nat Med* 2016; 22:762–770.
 49. Hessel AJ, Shapiro MB, Powell R, *et al.* Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges. *J Virol* 2018; 92; e02198-17.
- Efficacy of V2i mAbs passively administered to NHPs and challenged with SHIV_{BAL}.
50. Singh S, Ramirez-Salazar EG, Doueiri R, *et al.* Control of heterologous simian immunodeficiency virus SIVsmE660 infection by DNA and protein coimmunization regimens combined with different toll-like-receptor-4-based adjuvants in macaques. *J Virol* 2018; 92; e00281-18.
 51. Hessel AJ DM, Philip B, Shilpi P, *et al.* Tight Control of SHIV BaL.P4 Challenge in Rhesus Macaques Co-immunized With DNA and Protein HIV Vaccine Regimen. *HIV Research for Prevention*; Madrid. 2018. Abstract OA09.4.
 52. Weiss S, Vincenza I, Ruimin P, *et al.* Tight Control of SHIVBaL in Rhesus Macaques Immunized With gp160 DNA + gp120 Proteins (Clades E and B) Correlates With V2p Antibodies. *HIV Research for Prevention*; Madrid. 2018. Abstract OA14.06LB.
- First description of a correlate of protection from SHIV infection with the presence of V2p Abs.
53. Rolland M, Edlefsen PT, Larsen BB, *et al.* Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. *Nature* 2012; 490:417–420.
 54. Pollara J, Bonsignori M, Moody MA, *et al.* HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. *J Virol* 2014; 88:7715–7726.
 55. Desrosiers RC. Protection against HIV acquisition in the RV144 trial. *J Virol* 2017; 91; e00905-17.
 56. Mayr LM, Su B, Moog C. Non-neutralizing antibodies directed against HIV and their functions. *Front Immunol* 2017; 8:1590.
 57. Gach JS, Bouzin M, Wong MP, *et al.* Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. *PLoS Pathog* 2017; 13:e1006793.
 58. Perelson AS, Neumann AU, Markowitz M, *et al.* HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* 1996; 271:1582–1586.
 59. Alexander MR, Sanders RW, Moore JP, Klasse PJ. Short Communication: virion aggregation by neutralizing and nonneutralizing antibodies to the HIV-1 envelope glycoprotein. *AIDS Res Hum Retroviruses* 2015; 31:1160–1165.
 60. Liu P, Yates NL, Shen X, *et al.* Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. *J Virol* 2013; 87:7828–7836.
 61. Arthos J, Cicala C, Martinelli E, *et al.* HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. *Nat Immunol* 2008; 9:301–309.
 62. Lertjuthaporn S, Cicala C, Van Ryk D, *et al.* Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to alpha4beta7. *PLoS Pathog* 2018; 14:e1007278.
- HIV and SIV V2 mAbs elicited by both vaccination and infection block the interaction of V2 and $\alpha 4\beta 7$.
63. Peachman Kristina K, Karasavvas N, Chenine A-L, *et al.* Identification of new regions in HIV-1 gp120 variable 2 and 3 loops that bind to $\alpha 4\beta 7$ integrin receptor. *PLoS One* 2015; 10:e0143895.
 64. Alvarez RA, Hamlin RE, Monroe A, *et al.* HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. *J Virol* 2014; 88:6031–6046.
 65. Holl V, Peressin M, Decoville T, *et al.* Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. *J Virol* 2006; 80:6177–6181.
 66. Musich T, Li L, Liu L, *et al.* Monoclonal antibodies specific for the V2, V3, CD4-binding site, and gp41 of HIV-1 mediate phagocytosis in a dose-dependent manner. *J Virol* 2017; 91; e02325-16.
 67. Mayr LM, Decoville T, Schmidt S, *et al.* Nonneutralizing antibodies targeting the V1V2 domain of HIV exhibit strong antibody-dependent cell-mediated cytotoxic activity. *Sci Rep* 2017; 7:12655.
 68. Chung AW, Crispin M, Pritchard L, *et al.* Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. *AIDS* 2014; 28:2523–2530.
 69. Burton DR, Hessel AJ, Keele BF, *et al.* Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. *Proc Natl Acad Sci U S A* 2011; 108:11181–11186.
 70. Alvarez RA, Maestre AM, Law K, *et al.* Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. *JCI Insight* 2017; 2:e88226.
 71. Bonsignori M, Pollara J, Moody MA, *et al.* Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. *J Virol* 2012; 86:11521–11532.

72. Gomez-Roman VR, Patterson LJ, Venzon D, *et al.* Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. *J Immunol* 2005; 174:2185–2189.
73. Excler JL, Ake J, Robb ML, *et al.* Nonneutralizing functional antibodies: a new 'old' paradigm for HIV vaccines. *Clin Vaccine Immunol* 2014; 21:1023–1036.
74. Aasa-Chapman MM, Holuigue S, Aubin K, *et al.* Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. *J Virol* 2005; 79:2823–2830.
75. Spear GT, Landay AL, Sullivan BL, *et al.* Activation of complement on the surface of cells infected by human immunodeficiency virus. *J Immunol* 1990; 144:1490–1496.
76. Spear GT, Sullivan BL, Landay AL, Lint TF. Neutralization of HIV-1 by complement occurs by viral lysis. *J Virol* 1990; 64:5869–5873.
77. Sips M, Krykbaeva M, Diefenbach TJ, *et al.* Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. *Mucosal Immunol* 2016; 9: 1584–1595.
78. Ackerman ME, Mikhailova A, Brown EP, *et al.* Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. *PLoS Pathog* 2016; 12:e1005315.
79. Alter G, Dowell KG, Brown EP, *et al.* High-resolution definition of humoral immune response correlates of effective immunity against HIV. *Mol Syst Biol* 2018; 14:e7881.
- Systemic serological analysis of a cohort of HIV-infected individuals with varying degrees of viral control revealed multifaceted and coordinated contributions of polyclonal antibodies to diverse antiviral responses and suggests key biophysical features predictive of viral control.
80. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of fc receptor-bearing effector cells and correlate inversely with HIV infection rate. *J Immunol* 2007; 178:6596–6603.
81. Hidajat R, Xiao P, Zhou Q, *et al.* Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. *J Virol* 2009; 83:791–801.
82. Florese RH, Demberg T, Xiao P, *et al.* Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. *J Immunol* 2009; 182:3718–3727.
83. Xiao P, Zhao J, Patterson LJ, *et al.* Multiple vaccine-elicited nonneutralizing anti-envelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. *J Virol* 2010; 84:7161–7173.